Logo image of POAI

PREDICTIVE ONCOLOGY INC (POAI) Stock Fundamental Analysis

NASDAQ:POAI - Nasdaq - US74039M3097 - Common Stock - Currency: USD

1.42  -0.01 (-0.7%)

Fundamental Rating

1

POAI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of POAI have multiple concerns. POAI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

POAI had negative earnings in the past year.
POAI had a negative operating cash flow in the past year.
In the past 5 years POAI always reported negative net income.
POAI had a negative operating cash flow in each of the past 5 years.
POAI Yearly Net Income VS EBIT VS OCF VS FCFPOAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of POAI (-186.31%) is worse than 91.49% of its industry peers.
With a Return On Equity value of -710.24%, POAI is not doing good in the industry: 88.83% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -186.31%
ROE -710.24%
ROIC N/A
ROA(3y)-80.65%
ROA(5y)-106.47%
ROE(3y)-112.04%
ROE(5y)-302.57%
ROIC(3y)N/A
ROIC(5y)N/A
POAI Yearly ROA, ROE, ROICPOAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K

1.3 Margins

With a Gross Margin value of 43.06%, POAI is not doing good in the industry: 64.36% of the companies in the same industry are doing better.
POAI's Gross Margin has declined in the last couple of years.
POAI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-1.93%
POAI Yearly Profit, Operating, Gross MarginsPOAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

2

2. Health

2.1 Basic Checks

POAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for POAI has been increased compared to 1 year ago.
Compared to 5 years ago, POAI has more shares outstanding
Compared to 1 year ago, POAI has a worse debt to assets ratio.
POAI Yearly Shares OutstandingPOAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
POAI Yearly Total Debt VS Total AssetsPOAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -37.77, we must say that POAI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -37.77, POAI is doing worse than 90.43% of the companies in the same industry.
A Debt/Equity ratio of 0.10 indicates that POAI is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.10, POAI is in line with its industry, outperforming 59.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -37.77
ROIC/WACCN/A
WACC9.17%
POAI Yearly LT Debt VS Equity VS FCFPOAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M 40M

2.3 Liquidity

POAI has a Current Ratio of 1.20. This is a normal value and indicates that POAI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.20, POAI is doing worse than 86.17% of the companies in the same industry.
POAI has a Quick Ratio of 1.06. This is a normal value and indicates that POAI is financially healthy and should not expect problems in meeting its short term obligations.
POAI has a worse Quick ratio (1.06) than 74.47% of its industry peers.
Industry RankSector Rank
Current Ratio 1.2
Quick Ratio 1.06
POAI Yearly Current Assets VS Current LiabilitesPOAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

POAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.00%, which is quite impressive.
POAI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.81%.
POAI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.77% yearly.
EPS 1Y (TTM)34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.46%
Revenue 1Y (TTM)-23.81%
Revenue growth 3Y12.51%
Revenue growth 5Y4.77%
Sales Q2Q%-51.94%

3.2 Future

The Earnings Per Share is expected to grow by 38.67% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 1.44% on average over the next years.
EPS Next Y-1633.33%
EPS Next 2Y-4.08%
EPS Next 3Y38.67%
EPS Next 5YN/A
Revenue Next Year-90.58%
Revenue Next 2Y-20.59%
Revenue Next 3Y1.44%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
POAI Yearly Revenue VS EstimatesPOAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
POAI Yearly EPS VS EstimatesPOAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for POAI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for POAI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
POAI Price Earnings VS Forward Price EarningsPOAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
POAI Per share dataPOAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

POAI's earnings are expected to grow with 38.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.08%
EPS Next 3Y38.67%

More info and screens

0

5. Dividend

5.1 Amount

POAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PREDICTIVE ONCOLOGY INC

NASDAQ:POAI (2/11/2025, 11:58:39 AM)

1.42

-0.01 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners4.33%
Inst Owner Change-31.74%
Ins Owners1.7%
Ins Owner Change0%
Market Cap9.47M
Analysts43.33
Price Target3.06 (115.49%)
Short Float %6.98%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.87
P/FCF N/A
P/OCF N/A
P/B 4.82
P/tB 5.43
EV/EBITDA N/A
EPS(TTM)-3.06
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-1.93
FCFYN/A
OCF(TTM)-1.93
OCFYN/A
SpS0.21
BVpS0.29
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186.31%
ROE -710.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.06%
FCFM N/A
ROA(3y)-80.65%
ROA(5y)-106.47%
ROE(3y)-112.04%
ROE(5y)-302.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-1.93%
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.67%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.2
Quick Ratio 1.06
Altman-Z -37.77
F-Score3
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)49.73%
Cap/Depr(5y)37.75%
Cap/Sales(3y)38.79%
Cap/Sales(5y)29.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.46%
EPS Next Y-1633.33%
EPS Next 2Y-4.08%
EPS Next 3Y38.67%
EPS Next 5YN/A
Revenue 1Y (TTM)-23.81%
Revenue growth 3Y12.51%
Revenue growth 5Y4.77%
Sales Q2Q%-51.94%
Revenue Next Year-90.58%
Revenue Next 2Y-20.59%
Revenue Next 3Y1.44%
Revenue Next 5YN/A
EBIT growth 1Y10.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.03%
OCF growth 3YN/A
OCF growth 5YN/A